TACE联合索拉菲尼对中晚期肝癌患者血清HIF-1α、OPN水平的影响  

Effects of TACE combined with sorafenib on serum levels of HIF-1 alpha and OPN in patients with middle and advanced hepatocellular carcinoma

作　　者：吕达 王旭东[2] 朱海燕[3] 王法 LV Da;WANG Xudong;ZHU Haiyan(Department of Oncology,Qingdao Municipal Hospital,Shandong,Qingdao 266000,China)

机构地区：[1]山东省青岛市市立医院肿瘤科,266000 [2]山东省青岛市市立医院微创介入治疗科,266000 [3]山东省青岛市精神卫生中心检验科

出　　处：《河北医药》2019年第8期1144-1147,共4页Hebei Medical Journal

摘　　要：目的探讨肝动脉化疗栓塞(TACE)联合索拉菲尼对中晚期肝癌患者血清低氧诱导因子1α(HIF-1α)、骨桥素(OPN)水平的影响。方法选取中晚期肝癌患者120例,依据随机数字表法分为TACE组和索尼组,每组60例,TACE组给予TACE治疗,索尼组在此基础上给予索拉菲尼治疗,比较2组血清HIF-1α、OPN水平、肝功能[丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)]、治疗疗效、不良反应、生存情况。结果 TACE组和索尼组治疗后血清HIF-1α、OPN水平明显低于治疗前,索尼组治疗后血清HIF-1α、OPN水平明显低于TACE组,差异均有统计学意义(P<0.05);TACE组和索尼组治疗后ALT、AST、TBIL水平明显高于治疗前,差异有统计学意义(P<0.05),2组治疗后ALT、AST、TBIL水平比较,差异无统计学意义(P>0.05);索尼组治疗有效率明显高于TACE组,差异有统计学意义(P<0.05);TACE组和索尼组不良反应率比较,差异无统计学意义(P>0.05);索尼组1年生存率、中位生存时间明显高于TACE组,差异有统计学意义(P<0.05)。结论 TACE联合索拉菲尼可有效改善中晚期肝癌患者血清HIF-1α、OPN水平,也可改善患者肝功能,有利于提高患者生存预后,且安全性好。Objective To investigate the effects of transcatheter arterial chemoembolization (TACE) combined with sorafenib on the serum levels of hypoxia inducible factor 1 alpha (HIF-1 alpha) and osteopontin (OPN) in patients with middle and advanced hepatocellular carcinoma. Methods A total of 120 patients with middle and advanced hepatocellular carcinoma who were treated in our hospital from January 2016 to June 2017 were emrolled in the atusy.According to the random digital table method,these patients were divided into TACE group and sorafenib group,with 60 cases in each group.The patients in TACE group were treated by TACE,however,the patients in sorafenib group,on the basis of TACE group,were treated by sorafenib.After treatment the serum levels of HIF-1 alpha and OPN,liver function [alanine aminotransferase (ALT),aspartate aminotransferase (AST),total bilirubin (TBIL)],and therapeutic effects, adverse reactions,the survival condition of patients were observed compared between the two groups. Results After treatment the serum levels of HIF-1 alpha and OPN in both groups were significantly lower than those before treatment,moreover the serum levels of HIF-1 alpha and OPN in sorafenib group were significantly lower than those in TACE group ( P <0.05).After treatment the serum levels of ALT,AST,TBIL in both groups were significantly higher than those before treatment ( P <0.05),however, after treatment there were no significant differences in the serum levels of ALT,AST,TBIL levels between the two groups ( P >0.05).The therapeutic effect rate in sorafenib group was significantly higher than that in TACE group ( P <0.05). There was no significant difference in the incidence rate of adverse reactions between the two groups ( P >0.05).Moreover the 1-year survival rate and the median survival time in sorafenib group were significantly higher than those in TACE group ( P <0.05). Conclusion TACE combined with sorafenib can effectively improve the serum levels of HIF-1 alpha and OPN in patients with middle and advanced liver ca

关 键 词：肝动脉化疗栓塞 索拉菲尼 中晚期肝癌 低氧诱导因子1Α 骨桥素 

分 类 号：R735.7[医药卫生—肿瘤]